EQRx Raises White Flag On Its Low-Cost Drug Business Model
Executive Summary
The company is backing out of the development of several clinical-stage assets and will cut 170 positions while it changes its business strategy.
You may also be interested in...
Revolution Picks Up Remains Of EQRx In All-Stock Deal
Revolution Medicines is looking to pump the $1bn it will get from the acquisition into its RAS inhibitor pipeline, with trials planned to start in 2024.
EQRx Confronts US Drug Development Realities, Shifts Pricing Approach
Because of FDA requirements for studies applicable to US patients, EQRx ended US development of its PD-1 inhibitor and will launch its EGFR and CDK4/6 inhibitors at market-based prices.
EQRx Revises Plans To Get Chinese Licensed Drugs To US Market
The company has filed its first drug in the UK and initiated a US-based Phase III trial; US drug pricing legislation underscores the company's value proposition, CEO says.